6BG Stock Overview
A, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lytix Biopharma AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.68 |
| 52 Week High | NOK 1.04 |
| 52 Week Low | NOK 0.41 |
| Beta | -0.67 |
| 11 Month Change | 16.33% |
| 3 Month Change | -11.86% |
| 1 Year Change | 39.59% |
| 33 Year Change | -49.11% |
| 5 Year Change | n/a |
| Change since IPO | -56.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6BG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 32.6% | 1.9% | 1.5% |
| 1Y | 39.6% | -15.1% | 8.8% |
Return vs Industry: 6BG exceeded the German Biotechs industry which returned -15.1% over the past year.
Return vs Market: 6BG exceeded the German Market which returned 8.8% over the past year.
Price Volatility
| 6BG volatility | |
|---|---|
| 6BG Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6BG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6BG's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Oystein Rekdal | www.lytixbiopharma.com |
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.
Lytix Biopharma AS Fundamentals Summary
| 6BG fundamental statistics | |
|---|---|
| Market cap | €31.99m |
| Earnings (TTM) | -€6.96m |
| Revenue (TTM) | €924.84k |
34.6x
P/S Ratio-4.6x
P/E RatioIs 6BG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6BG income statement (TTM) | |
|---|---|
| Revenue | NOK 10.76m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 10.76m |
| Other Expenses | NOK 91.68m |
| Earnings | -NOK 80.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 100.00% |
| Net Profit Margin | -752.26% |
| Debt/Equity Ratio | 0% |
How did 6BG perform over the long term?
See historical performance and comparison